Baron Asset Fund Q3 2025 Performance Review
Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. From a sector perspective, stock selection in IT...
Fiscal Year: January - December
IDEXX Laboratories, Inc. (IDXX), listed on the NASDAQ, has a market capitalization of $. As of Nov 19, 2025, the stock is trading at $697.10 per share, offering investors a clear view of its current market value. IDEXX Laboratories, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 55.32, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. IDEXX Laboratories, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that IDEXX Laboratories, Inc. (IDXX) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for IDEXX Laboratories, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for IDEXX Laboratories, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for IDEXX Laboratories, Inc. is 57.83, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, IDEXX Laboratories, Inc. (IDXX) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether IDEXX Laboratories, Inc. (IDXX) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of IDEXX Laboratories, Inc. (IDXX) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of IDEXX Laboratories, Inc.. To access the full SS Score, consider upgrading your subscription.
IDEXX Laboratories, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 55.32. Investors should compare these metrics with industry peers to gauge whether IDEXX Laboratories, Inc. is outperforming or underperforming within its sector.
Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. From a sector perspective, stock selection in IT...
IDEXX Laboratories (IDXX) continues to outperform the S&P 500, driven by strong recurring revenue and a robust customer ecosystem. IDXX delivered a double beat in Q3, with revenue up 13% and EPS up 21...
IDEXX Laboratories, Inc. ( IDXX) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jay Mazelsky - President, CEO & Director Confer...
Vet visits are down, but growing revenue per visit is more than making up for it, the company says.
IDEXX Laboratories Inc.‘s (NASDAQ:IDXX) stock is trading higher on Monday after it reported better-than-expected third-quarter financial results and raised its 2025 forecast.
IDEXX Laboratories raised its full-year profit and revenue forecasts on Monday after reporting better third-quarter results than last year, as the pet diagnostics maker banks on owners spending more o...
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company repor...
IDEXX Laboratories, Inc. (NASDAQ:IDXX) will release earnings results for the third quarter, before the opening bell on Monday, Nov. 3.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Mond...
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Direct...
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Jay Mazelsky - President, CEO & Director Andrew Emers...
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and ...
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...
Major U.S. equities indexes pushed higher at the top of the new trading week, bouncing back from declines posted ahead of the weekend. Although weaker-than-expected jobs data released on Friday raised...
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jonathan J. Mazelsky - President,...
U.S. equities were higher at midday, bouncing back from Friday's employment report-related selloff, and on news the European Union would delay new tariffs on U.S. goods. The Dow Jones Industrial Avera...
Pet healthcare is witnessing a surge in demand as more households prioritize their pets' well-being, driving companies in this sector to outperform expectations. This trend is reflected in IDEXX Labor...
Shares of IDEXX Laboratories (IDXX) soared more than 10% in premarket trading Monday after the pet health care company reported better-than-expected second-quarter results and raised its 2025 profit a...
IDEXX Laboratories raised its full-year profit and revenue forecasts on Monday after reporting better-than-expected second-quarter results, driven by strong demand for its veterinary diagnostic equipm...
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. “Our innovation-driven strategy delive...
WESTBROOK, Maine , July 30, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today released its 2024 Corporate Responsibility Report "Enhanci...
I rate IDEXX Laboratories a buy, driven by a lasting surge in pet ownership and IDXX's leadership in veterinary diagnostics. New platforms like inVue Dx and Cancer Dx provide additional growth drivers...
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board ...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 977.84M | 21.01% | Est @21.0% |
| 2026 | 1,147.60M | 17.36% | Analyst x4 |
| 2027 | 1,294.33M | 12.79% | Analyst x3 |
| 2028 | 1,464.00M | 13.11% | Analyst x2 |
| 2029 | 1,684.00M | 15.03% | Analyst x1 |
| 2030 | 1,808.78M | 7.41% | Est @7.4% |
| 2031 | 1,915.95M | 5.93% | Est @5.9% |
| 2032 | 2,009.50M | 4.88% | Est @4.9% |
| 2033 | 2,092.85M | 4.15% | Est @4.1% |
| 2034 | 2,163.90M | 3.39% | Est @3.4% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 772.88M | 1.00 | 772.88M |
| 2024A | 808.08M | 1.00 | 808.08M |
| 2025E | 977.84M | 1.10 | 886.49M |
| 2026E | 1.15B | 1.22 | 943.19M |
| 2027E | 1.29B | 1.34 | 964.40M |
| 2028E | 1.46B | 1.48 | 988.91M |
| 2029E | 1.68B | 1.63 | 1.03B |
| 2030E | 1.81B | 1.80 | 1.00B |
| 2031E | 1.92B | 1.99 | 964.31M |
| 2032E | 2.01B | 2.19 | 916.90M |
| 2033E | 2.09B | 2.42 | 865.72M |
| 2034E | 2.16B | 2.67 | 811.49M |
| Terminal | 28.42B | 2.67 | 10.66B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.